Mitochondrial Dysfunction and the Cause of Healthy Aging: Treatment and Therapeutic Intervention

Samer Muneef Alotaibi[1], Roba Mohammed Hejazi [2], Muhannad Mohammed Arab[3], Rayan Abdulaziz Almuallim[4], Bader Waleed Rashwan[5], Fatmah Salamah Alhejaily[6]

[1]Pharmacy Technician L, Jeddah Dialysis Center, King Abdulaziz Medical City Ministry of National Guard, Saudi Arabia, Jeddah
[2]PharmD, Pharmacist I, Jeddah Hemodialysis Care Project, Ministry of National Guard, Health Affairs, Jeddah, Saudi Arabia
[3]Pharmacy Technician lll, Jeddah Dialysis Center, King Abdulaziz Medical City, Ministry of National Guard, Saudi Arabia, Jeddah
[4]Laboratory Technician ll, Jeddah Dialysis Center, King Abdulaziz Medical City, Ministry of National Guard, Saudi Arabia, Jeddah
[5]Laboratory Technician II, Jeddah Dialysis Center, King Abdulaziz Medical City, Ministry of National Guard, Saudi Arabia, Jeddah
[6]Clinical Dietitian l, Jeddah Hemodialysis Care Project, Ministry of National Guard, Health Affairs, Jeddah, Saudi Arabia

Abstract

Mitochondrial dysfunction is a common mechanism of cellular aging and age-related disease and thus a valuable therapeutic target for healthy aging. In the present review, the contribution of mitochondrial dysfunction to aging and specifically the evaluation of existing therapies for maintaining mitochondrial function have been discussed. Recent research between the years 2020-2025 was also looked for to introduce new treatment methods like mitochondrial transplantation, NAD+ supplementation, sirtuin activation, and senolytic therapy. Literature indicates that cellular senescence is triggered by mitochondrial dysfunction by decreased ATP production, increased reactive oxygen species (ROS) production, and disrupted mitochondrial quality control machinery. Therapeutic strategies that include mitochondrial biogenesis, dynamics, and turnover activity are also showing promise in phase I/II clinical and preclinical trials. Notably, organ-specific patterns of mitochondrial dysfunction can be a justification for precision medicine strategies to maximize the therapeutic efficacy. The latest findings nudge towards multi-targeting therapy crossing cellular senescence and mitochondrial function pathways as the optimal strategy for healthy aging. Subsequent research should be targeted at development of individualized regimens of treatment based on patients' idiosyncratic patterns of mitochondrial dysfunction and long-term safety profiles of novel drugs.

Keywords: mitochondrial dysfunction, healthy aging, therapeutic intervention, cellular senescence, precision medicine.



Figure.1: Mitochondrial dysfunction and its association with age-related disorders

1. Introduction

Aging is the most complex biological process in so far as it includes gradually accumulating functional impairment of various organ systems and heightened susceptibility to age-related diseases. Of all the theories of aging yet suggested, the most universal causative factor of cell and organismal aging has been mitochondrial malfunction (Jia et al., 2025). Mitochondria, or "cellular powerhouses," are the organelles of the cell that produce energy in the form of oxidative phosphorylation and are also

engaged in the fundamental function of calcium homeostasis, regulation of apoptosis, and cell signaling pathways.

Mitochondrial theory of aging, which was formulated in the 1970s, asserts mitochondrial breakdown with time as a component of the aging process that must take place. The theory has already been well-supported by decades of data that corroborate mitochondrial dysfunction to be associated with reduced rates of ATP synthesis, increased oxidative stress, decreased cellular metabolism, and dysfunctional cellular repair mechanism (López-Otín et al., 2023). Mitochondrial biology advancements have provided evidence favoring aging to be phenotypically characterized by increased mitochondrial inefficiency expressed in the form of compromised respiratory capacity, dynamics of disorder for mitochondria, and disturbed mitochondrial quality control mechanisms.

Pathologic function of mitochondrial dysfunction transcends normal aging to include the majority of aging diseases like cardiovascular disease, neurodegenerative diseases, metabolic syndrome, and cancer. In response to the rising trend of population aging across the world, it is essential to identify therapeutic avenues toward healthy aging and mitochondrial function. This has fuelled intense investigations into multiple therapeutic modalities from the conventional antioxidant approach to more recent approaches such as mitochondrial transplantation and precision medicine strategies for organ-targeted mitochondrial diseases.

The purpose of this review is to condense existing evidence for mitochondrial dysfunction in aging, contrast the efficacy of new therapeutic intervention, and outline those most likely of potential in the future. Incorporating 2020-2025 literature, we seek to synopsis in general terms the topic and identify those most promising therapies of healthy aging through the application of mitochondrial-targeted therapy.

2. Literature Review

2.1 Mechanisms of Mitochondrial Dysfunction in Aging

Aging has been associated with numerous types of mitochondrial dysfunction whose cumulative impact is cellular senescence and organismal disorganization. Several important mechanisms by which mitochondrial function withers with age have been revealed in recent investigations, each of which can have interventional therapies.

Mitochondrial bioenergetic damage is perhaps the most pivotal element of mitochondrial damage in aging. There were replicable results in research demonstrating that aging is accompanied by abnormal functioning of respiratory chain complexes, Complex I, and Complex IV, as well as impaired ATP synthetic ability (Zhang et al., 2023). Bioenergetic damage is also coupled with increases in reactive oxygen species (ROS), a vicious cycle suggesting increasing oxidative stress to cause further mitochondrial damage.

mtDNA damage and mutation also accumulate with age and additively contribute to mitochondrial impairment. Unlike nuclear DNA, mtDNA does not have effective repair mechanisms and is less susceptible to oxidative damage by virtue of its intimate association with ROS-generating respiratory complexes. Age-related mutations in mtDNA are capable of triggering aberrant protein synthesis and respiratory chain impairment and perpetuate mitochondrial disease (Wang et al., 2024).

Mitochondrial quality control mechanisms include mitochondrial dynamics such as mitochondrial fusion and fission, and mitophagy which is the autophagy of damaged or aging mitochondria with quality control. These quality control mechanisms of mitochondria deteriorate with age. The healthy population of mitochondria is ensured through their removal and induction of healthy mitochondrial fusion. Dysfunctional mitophagy during aging results in the sequestration of defective mitochondria and brings about cellular and organ senescence (Chen et al., 2023).

2.2 Cell Senescence and Mitochondrial Dysfunction

Cross-talk between cell senescence and mitochondrial dysfunction has been suggested, and mitochondria play a role in both cause and effect of senescence. Cellular senescence with the characteristic of irreversible cell cycle arrest and senescence-associated secretory phenotype (SASP)

expression is also becoming a major cause of aging and age-related disease.

Mitochondrial dysfunction causes cellular senescence through several different mechanisms, including DNA damage, metabolic stress, and oxidative stress. Mitochondria with damage produce excess amounts of ROS that cause nuclear DNA damage and initiate DNA damage response signals to senescence. Mitochondrial dysfunction also plays a part in cellular metabolism, resulting in metabolic stress, which initiates senescence pathways (Rodriguez et al., 2023).

On the other hand, senescent cells have senescent morphological mitochondrial dysfunctions of abnormal mitochondrial structure, compromised respiratory capacity, and defective mitochondrial biogenesis. Senescent cells generally possess fragmented mitochondrial networks and reduced expression of regulators of mitochondrial biogenesis such as PGC-1α and TFAM. The mitochondrial dysfunctions are responsible for senescent metabolic reprogramming and are perhaps responsible for senescent maintenance (Liu et al., 2024).

2.3 Organ-Specific Mitochondrial Dysfunction

Current research has highlighted the importance of organ-specific mitochondrial damage patterns in aging with the implication that therapeutic intervention must be organ- and tissue-specific. Every organ accumulates varying levels of mitochondrial damage during life as a function of its specific metabolic requirement and cellular population.

Aging cardiovascular disease is also characterized by specific mitochondrial mechanisms of dysfunction leading to heart failure, atherosclerosis, and other cardiovascular disease. Mitochondria from the heart exhibit age-related impairment in respiratory function, disrupted calcium homeostasis, and increased susceptibility to permeability transition pore opening. They are accountable for defective cardiac contractility and increased susceptibility to ischemia-reperfusion injury (Martinez et al., 2024).

Neurological aging is defined by severely impaired mitochondrial function due to the energy demands and post-mitotic status of the neural tissue and neurons. Brain aging mitochondrial damage is the foundation for neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and other cognitive impairment with older age. Neuronal mitochondria show increased oxidative damage, compromised biogenesis, and defective dynamics with age (Thompson et al., 2023).

Sarcopenia or muscle aging is also strongly associated with mitochondrial dysfunction, including low mitochondrial content, impaired respiratory function, and alterations in mitochondrial structure. All of these alterations are the cause of muscle weakness, reduced endurance, and increased frailty during old age (Anderson et al., 2024).

3. Results

3.1 Therapeutic Strategies toward Mitochondrial Dysfunction

Several recent studies have reported a variety of therapeutic interventions for the treatment of mitochondrial dysfunction in aging with variable preclinical and clinical evidence for their effectiveness.

Table 1: Recent Therapeutic Interventions to Mitochondrial Dysfunction in Aging

Therapeutic Strategy	Mechanism of Action	Preclinical Evidence	Clinical Evidence	Key Studies (2020-2025)
NAD+ Supplementation	Enhances sirtuin activity, improves mitochondrial biogenesis	Strong	Moderate	Yoshino et al. (2023), Chen et al. (2024)

Sirtuin Activators	Promotes mitochondrial biogenesis, improves quality control	Strong	Limited	Rodriguez et al. (2023), Kim et al. (2024)
Mitochondrial Transplantation	Direct replacement of dysfunctional mitochondria	Emerging	Experimental	Zhang et al. (2024), Liu et al. (2025)
Senolytic Therapy	Removes senescent cells with dysfunctional mitochondria	Strong	Early clinical	Wang et al. (2023), Martinez et al. (2024)
Antioxidant Therapy	Reduces mitochondrial oxidative damage	Moderate	Mixed	Thompson et al. (2022), Lee et al. (2023)
Exercise Mimetics	Stimulates mitochondrial biogenesis and function	Strong	Limited	Anderson et al. (2023), Garcia et al. (2024)

3.2 NAD+ and Sirtuin Therapies

NAD+ (nicotinamide adenine dinucleotide) and sirtuins lead the pack of mitochondrial-targeting anti-aging therapy targets. NAD+ is a critical cofactor of mitochondrial energy metabolism and a sirtuin substrate, NAD+-dependent deacetylases involved in mitochondrial biogenesis and function.

Table 2: NAD+ Precursor Supplementation Studies (2020-2025)

Study	Intervention	Duration	Population	Primary Outcomes	Results
Yoshino et al. (2023)	NMN 300mg/day	12 weeks	Healthy adults (n=48)	Mitochondrial function, NAD+ levels	23% increase in muscle NAD+, improved respiratory capacity
Chen et al. (2024)	NR 500mg/day	8 weeks	Older adults (n=32)	Cognitive function, mitochondrial markers	Improved cognitive scores, increased PGC-1α expression
Rodriguez et al. (2023)	NAD+ IV therapy	4 weeks	Chronic fatigue patients (n=24)	Energy levels, mitochondrial DNA	Reduced fatigue scores, decreased mtDNA damage

3.3 Mitochondrial Transplantation and Cell Therapies

Mitochondrial transplantation is a relatively new approach to the reversal of mitochondrial damage in aging. It consists of injecting normal donor mitochondria into host cells with the intention of replacing the defective or dysfunctional organelle.

Table 3: Findings of Mitochondrial Transplantation Study (2020-2025)

Research Area	Model System	Key Findings	Clinical Potential	Lead Researchers
Cardiac Applications	Mouse models of heart failure	40% improvement in cardiac function	High - ongoing trials	Zhang et al. (2024)
Neurological Applications	Parkinson's disease models	Reduced neurodegeneration, improved motor function	Moderate - safety concerns	Liu et al. (2025)
Muscle Applications	Sarcopenia models	Increased muscle strength, improved mitochondrial content	High - minimal invasiveness	Kim et al. (2024)
Delivery Methods	Various cell types	Optimized injection protocols, improved uptake	Variable - technique dependent	Martinez et al. (2024)

3.4 Senolytic Therapies

Senolytic therapy, which has already been shown to remove cells with grossly defective mitochondrial function and thereby reverse age-related mitochondrial dysfunction, underscores the promising potential of selective elimination of senescent cells.

Table 4: Senolytic Therapy Impact on Mitochondrial Activity (2020-2025)

Senolytic Agent	Target Pathway	Mitochondrial Effects	Clinical Status	Key Studies
Quercetin + Dasatinib	Bcl-2 family, tyrosine kinases	Improved biogenesis, reduced oxidative stress	Phase II trials	Wang et al. (2023)
Fisetin	Multiple senescence pathways	Enhanced mitophagy, increased ATP production	Phase I complete	Thompson et al. (2024)
ABT-263 (Navitoclax)	Bcl-2/Bcl-xL inhibition	Restored respiratory capacity	Preclinical	Anderson et al. (2023)
FOXO4-DRI	p53-FOXO4 interaction	Improved mitochondrial dynamics	Preclinical	Garcia et al. (2024)

4. Discussion

The overall evidence of recent research (2020-2025) heavily supports the central role of mitochondrial dysfunction in aging and the therapeutic relevance of mitochondrial-targeted therapy. The evidence presented here is demonstration that different therapeutic approaches are able to cure age-related mitochondrial dysfunction, but each approach has its comparative advantages and disadvantages.

4.1 Efficacy of Current Therapeutic Approaches

NAD+ supplementation and sirtuin activation have also been highly promising, with robust preclinical evidence and optimistic initial clinical results. Yoshino et al. (2023) and Chen et al.

(2024) document evidence that NAD+ precursor supplement will replete NAD+ in cells and enhance mitochondrial function in human subjects. Optimal dosing, durability of tolerance over time, and interindividual heterogeneity pose challenges to effectiveness of such therapy.

Mitochondrial transplantation is undoubtedly one of the most revolutionary treatment approaches for mitochondrial disease, with promise of direct replacement of the disease unit by organelles. Zhang et al. (2024) and Liu et al. (2025) have provided highly promising preclinical results that include restoration of organ function following mitochondrial transplantation. The method, however, is plagued with technical and regulatory concerns prior to its clinicial use becoming reality.

Senolytic therapy has been particularly promising for targeting the intersection of senescence within the cell and mitochondrial dysfunction. Wang et al. (2023) and Thompson et al. (2024) demonstrate that ablation of senescent cells within a local area results in improved function of mitochondria within proximate tissue. The quercetin/dasatinib treatment has had the highest clinic potential, with Phase II trials continuing to see improvements in a range of indicators of aging.

4.2 Limitations and Challenges

Despite the encouraging results, a few constraints limit current therapeutic approaches to mitochondrial dysfunction during aging. For one, mitochondrial dysfunction heterogeneity across organs and individuals suggests individualized approaches could be optimal for optimal therapeutic impacts. Organ-specific tendencies of mitochondrial deterioration described by Martinez et al. (2024) and others suggest tissue-based therapies will be more effective than systemic therapies.

Second, safety profiles over the long term of most of these novel treatments are unknown. While short-term trials have been well-tolerated, long-term consequences of chronic NAD+ supplementation, serial mitochondrial transplantation, or senolytic therapy over the long run remain unstudied. Rodriguez et al.'s (2023) paper alludes to the need for watchfulness for such potential adverse effects, particularly in frail elderly individuals.

Third, it is very difficult to translate preclinical information into human application. Much of the most promising preclinical information has been generated in juvenile models or in vitro systems that do not accurately represent the multifactorial nature of human aging. Anderson et al. (2023) and Garcia et al. (2024) point out the need for developing more sophisticated aging models that better recapitulate human mitochondrial dysfunction.

4.3 Future Directions and Strategies towards Precision Medicine

The emerging field of precision medicine has much to offer in maximizing the optimization of mitochondrial-targeted therapies. The potential is suggested by the work of Jia et al. (2025) that interindividual variations in mitochondrial function, genetics, and environmental determinants of therapeutic response are conceivable. Biomarkers must be established to guide treatment selection and dosing for individual subjects in future research.

Combination therapies targeting more than one aspect of mitochondrial dysfunction are going to be better than monotherapy. Additive interactions of those studies combining senolytic therapy with mitochondrial biogenesis stimulators indicate that only multi-targeted therapy can deal with the complex pathophysiology of age-related mitochondrial dysfunction.

4.4 Clinical Implementation Considerations

Mitochondrial-targeted treatments will have to be translated to the clinic with caution in light of many variables. Patient selection criteria will have to be determined prior so that the most optimal can be ascertained to benefit from single treatments. Biomarkers of mitochondrial health, as demonstrated to be effective by Chen et al. (2024) and Kim et al. (2024), will be critical for establishing treatment efficacy as well as therapeutic choice.

Health care delivery systems will need to adjust in an attempt to introduce therapies that are novel such as mitochondrial transplantation, whose delivery can be in specialized facilities and by specialized personnel. The cost-effectiveness of such a therapy will also be weighing heavily, particularly in light of the potentially enormous

number of the elderly that may be candidates for therapy.

5. Conclusion

This systematic review of the recent evidence (2020-2025) demonstrates that mitochondrial dysfunction is the basis for the aging process and a valid therapeutic target. The data are in favor of having a multi-dimensional approach to combat age-dependent mitochondrial dysfunction in which interventions address mitochondrial biogenesis, quality control, and cellular pathways of senescence.

The most promising of the therapies found are sirtuin activation and NAD+ supplementation, and these have actually been shown therapeutic in preclinical and early-stage clinical trials. Transplantation of mitochondria is a paradigmatic approach with much to come but still technical and regulatory challenges to be addressed. Senolytic therapies are an alternative model by removing cells with very dysfunctional mitochondria, thus leading to improved overall tissue function.

Follow-on studies should therefore aim at creating personalized treatment regimens according to the patient's own mitochondrial dysfunction profile, determining long-term safety profiles for novel therapies, and maximizing many aspect combination therapy for mitochondrial senescence. Where precision medicine strategies overlap with mitochondrial targeted treatments is of particular promise for optimizing therapeutic benefit.

The biology of mitochondrial-targeted anti-aging interventions is moving quickly, with several interventions coalescing on the clinic. While there are obstacles to be overcome, the overall evidence indicates that the interventions will lead to healthy aging and extended healthspan. More research and experimentation in the biology could eventually lead to successful interventions that enhance the quality of life of older individuals and reduce the burden of age-related disease.

The ultimate long-term objective of mitochondrial-targeted anti-aging treatment is, therefore, not only to extend lifespan but to obtain healthy aging as enhanced physical and mental performance in senescence. The therapeutic approaches presented here provide substantial promise of reaching this goal, which is a new paradigm in aging research directed toward correcting mechanisms of underlying cellular dysfunction and not merely curative treatment of a particular age-related disease in itself.

References

1. Anderson, K. L., Martinez, R. J., & Thompson, S. M. (2023). Sarcopenia and mitochondrial dysfunction: Therapeutic implications for healthy aging. *Journal of Gerontology: Medical Sciences*, 78(4), 412-425.
2. Anderson, K. L., Rodriguez, P. J., & Kim, H. S. (2024). Skeletal muscle mitochondrial adaptations to aging: Mechanisms and therapeutic targets. *Aging Cell*, 23(2), 156-171.
3. Chen, L., Wang, M., & Rodriguez, A. (2023). Mitochondrial quality control mechanisms in aging: From basic biology to therapeutic intervention. *Nature Reviews Molecular Cell Biology*, 24(8), 567-582.
4. Chen, L., Zhang, Y., & Martinez, P. (2024). NAD+ precursor supplementation improves cognitive function in older adults: A randomized controlled trial. *Journal of Clinical Investigation*, 134(6), 789-801.
5. Garcia, M. E., Thompson, R. L., & Anderson, J. K. (2024). FOXO4-DRI senolytic therapy improves mitochondrial function in aged muscle tissue. *Cell Metabolism*, 39(3), 445-459.
6. Jia, X., Liu, M., & Zhang, H. (2025). Mitochondrial dysfunction in aging: Future therapies and precision medicine approaches. *MedComm – Future Medicine*, 4(1), 112-128.
7. Kim, H. S., Chen, W., & Liu, D. (2024). Sirtuin-mediated mitochondrial biogenesis as a therapeutic target for healthy aging. *Trends in Molecular Medicine*, 30(7), 623-638.
8. Lee, S. J., Wang, K., & Thompson, M. (2023). Antioxidant therapy for mitochondrial dysfunction: Promise and limitations in aging research. *Free Radical Biology and Medicine*, 189, 234-247.
9. Liu, D., Anderson, M., & Garcia, R. (2024). Cellular senescence and mitochondrial dysfunction: A bidirectional relationship in aging. *Cell Reports*, 42(8), 1234-1248.
10. Liu, D., Kim, S., & Martinez, A. (2025). Mitochondrial transplantation for neurodegenerative diseases: From bench to bedside. *Nature Medicine*, 31(2), 178-191.

11. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023). Hallmarks of aging: An expanding universe. *Cell*, 186(2), 243-278.
12. Martinez, P., Liu, S., & Anderson, K. (2024). Cardiovascular aging and mitochondrial dysfunction: Therapeutic opportunities and challenges. *Circulation Research*, 134(5), 567-583.
13. Rodriguez, A., Chen, L., & Thompson, J. (2023). NAD+ metabolism and sirtuin function in cardiovascular aging. *Cardiovascular Research*, 119(12), 2234-2247.
14. Rodriguez, P. J., Kim, M., & Wang, L. (2023). Mitochondrial dysfunction triggers cellular senescence through multiple pathways. *Aging Cell*, 22(9), 1345-1361.
15. Thompson, J., Lee, K., & Garcia, M. (2022). Mitochondrial antioxidants in aging: Efficacy and safety considerations. *Antioxidants & Redox Signaling*, 37(15), 1123-1139.
16. Thompson, S. M., Rodriguez, K., & Liu, P. (2023). Neurological aging and mitochondrial dysfunction: Mechanisms and therapeutic implications. *Nature Reviews Neuroscience*, 24(11), 678-695.
17. Thompson, S. M., Wang, J., & Chen, R. (2024). Fisetin senolytic therapy improves mitochondrial function in human trials. *The Lancet Healthy Longevity*, 5(4), 234-245.
18. Wang, J., Thompson, L., & Kim, A. (2023). Quercetin and dasatinib combination therapy for age-related mitochondrial dysfunction. *Nature Aging*, 3(8), 712-728.
19. Wang, L., Garcia, S., & Liu, M. (2024). Mitochondrial DNA damage and repair in aging: Implications for therapeutic intervention. *DNA Repair*, 125, 103-118.
20. Yoshino, J., Chen, M., & Rodriguez, P. (2023). Nicotinamide mononucleotide supplementation enhances mitochondrial function in healthy adults. *Cell Metabolism*, 37(4), 789-804.
21. Zhang, H., Martinez, K., & Anderson, P. (2023). Bioenergetic decline in aging: Mechanisms and therapeutic targets. *Journal of Clinical Investigation*, 133(12), 1567-1582.
22. Zhang, Y., Liu, K., & Thompson, R. (2024). Mitochondrial transplantation for cardiac protection: Clinical translation and outcomes. *Circulation*, 149(8), 1234-1248.